Please login to the form below
Inclisiran
This page shows the latest Inclisiran news and features for those working in and with pharma, biotech and healthcare.
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
mark. The company also said it had resubmitted its cholesterol-lowering med inclisiran in the US, after the Food and Drug Administration (FDA) issued a Complete Response Letter earlier this year ... In the EU, inclisiran is already approved under the
Latest news
-
Novartis announces delay in UK cholesterol drug study
Leqvio (inclisiran) is a small interfering RNA (sIRNA) with a new mechanism of action that allows it to deliver effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction for patients
-
Novartis scores CHMP backing for cholesterol drug Leqvio
Leqvio ( inclisiran) is a potential first-in-class treatment for high cholesterol in Europe for patients with hypercholesterolemia or mixed dyslipidemia.
-
Esperion gets FDA thumbs up for cholesterol drug Nexletol
and Sanofi/Regeneron – and could see a launch later this year for Novartis’ PCSK9 drug inclisiran. ... Inclisiran – a gene-silencing drug – which can be dosed just twice a year after an initial loading period – is expected to mount a strong
-
Novartis plans inclisiran trial in the UK
In January, Novartis announced that it has teamed up with the NHS which will see patients in England receive accelerated access to inclisiran upon regulatory approval. ... Novartis acquired inclisiran from The Medicines Company, after a completing a
-
Cosentyx, Entresto drive topline growth for Novartis in Q4
These new drugs are expected to continue to drive growth into 2020 – newly acquired cholesterol drug inclisiran, gained from Novartis’ acquisition of The Medicines Company, is also expected to reach impressive
More from news
Approximately 10 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
8. Inclisiran from The Medicines Company (now a Novartis wholly owned subsidiary) is being reviewed for approval in hypercholesterolemia in the US and the EU. ... Inclisiran must leverage its strong efficacy and twice-a-year dosing to succeed.
-
20 for 2020 – Five pharma leaders to watch in 2020
Meanwhile, there’s considerable excitement about Novartis-partnered cholesterol-lowering therapy inclisiran, which is also up for an FDA decision this year and has been tipped to become a mega-blockbuster
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for hypercholesterolemia being co-developed by the Medicines Company; and lumisiran
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
No results were found
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
